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Aims To examine differences in patient characteristics and outcomes in 19 636
patients enrolled in the USA and 3027 patients enrolled in other countries undergoing
intra-aortic balloon pump (IABP) counterpulsation.
Methods and results Indications for IABP use; a larger percentage of US patients were
identified as ‘early support and stabilization for angiography or angioplasty’ (21.1% US
vs 11.8% non-US), and ‘pre-operative support for high-risk CABG’ (15.9% vs 6.6%). A
smaller percentage of US patients vs non-US patients were identified as ‘weaning from
cardiopulmonary bypass’ (14.3% vs 28.2%), and ‘refractory ventricular failure’ (6.2% vs
9.8%). One out of five patients in both groups was listed as ‘cardiogenic shock’ (18.9%
US vs 20.2% non-US). All cause, risk-adjusted, in-hospital mortality (20.1% vs 28.7%;
P<0.001), and mortality with IABP in place (10.8% vs 18.0%; P<0.001) were lower at US
vs non-US sites. In both US and non-US institutions, IABP associated complication
rates, such as IABP-related mortality (0.05% vs 0.07%), major limb ischaemia (0.9% vs
0.8%), and severe bleeding (0.9% vs 0.8%), were low.
Conclusions IABP counterpulsation is deployed at an earlier clinical stage in US
patients. Mortality rates are higher for non-US patients, particularly for patients with
non-surgery cardiac interventions, even after adjusting for risk factors. Complication
rates were low. Physicians should therefore not be reluctant to use IABP in high-risk
patients undergoing cardiac procedures.
© 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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Introduction
International registries are important tools for analysing
disease management and outcomes among different
nations. Exploration of such data may lead to changes in
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national health care policies and disease management
strategies.1 International registries in the United States
(US) and Europe have documented regional differences in
patient care, and as discrepancies have been identified,
have helped to change patient care.2 Patient treatment
can vary substantially from region to region, as can
baseline patient characteristics. For example, even
within Europe, there is substantial geographic variation
in the treatment and evaluation of acute coronary
syndromes.3
The Benchmark counterpulsation outcomes registry is
a prospective registry of all patients who receive an
intra-aortic balloon counterpulsation (IABP) at partici-
pating institutions. An overview of the outcomes4
revealed that IABP complication rates are low, although
all cause in-hospital mortality remains high, particularly
in high-risk patients. The primary aim of the present
study is to examine differences in baseline character-
istics, patient management, and outcomes between
patients in the US and outside the US undergoing IABP
from June 1996 through August 2001.
Methods
The Benchmark Counterpulsation Outcomes Registry currently
includes 185 US sites and 65 non-US sites that use intra-aortic
balloons manufactured by Datascope Corporation, Fairfield NJ,
USA. Of the 22 663 patients enrolled in the Benchmark registry,
19 636 (87%) were enrolled in the US, and 3027 (13%) were
enrolled in 18 other countries (Appendix A). Any patient at a
participating hospital who received an IABP was entered into
the database. Patients were registered consecutively to avoid
biased selection of cases and were followed to hospital dis-
charge. Concomitant medications were left to the discretion of
the treating physician. Information on data collection, handling,
and validation has been previously published.4 Briefly, all
data were collected by nurses with oversight provided by site
investigators. Three separate audits were used to validate the
accuracy of the data.5 Datascope Corporation provided funding
for the database.
Statistics
For quantitative variables, such as age, the Student's t-test was
applied to the ranks of the observations within the combined
sample, a method also known as a rank transformation. For
categorical variables, P values were determined by using a
chi-square test comparing the US distribution versus non-US
distribution over the categories. Data on prophylactic use are
based on IABP insertion before an intervention (not during or
after an intervention). Cardiac interventions were categorized
as surgical or non-surgical interventions. If patients had more
than one intervention, then only the last intervention was used.
Multiple logistic regression was used to compare the US and
non-US in-hospital mortality experience after adjusting for mor-
tality risk factors. Factors were chosen using model-building
procedures developed from previous work with the Benchmark
Registry. Potential factors were screened and models were
generated in a stepwise procedure. First, individual factors were
screened using two-way crosstabulations of the factor cat-
egories with in-hospital mortality, or by determining whether
mortality/non-mortality groups separate the means of continu-
ous factors. Generally, only factors with a statistically signifi-
cant association (P<0.05) were included in the full model.
Second, factors chosen in the first step were entered in a full
logistic regression model. The effects of collinearity were deter-
mined as a reduction of predictive value in the full model of a
factor that individually had a strong apparent relationship with
in-hospital mortality. Third, non-significant factors (P>0.05)
were eliminated from the full model in the following order, first
interactions, then the individual factors. If an interaction was
statistically significant, then the individual factors making
up the interaction were automatically retained in the model
regardless of their individual significance. Fourth, likelihood
Table 1 Patient characteristics and prior history
Total
n=22663
US institutions
n=19636
Non-US institutions
n=3027
P
valuea
Patient age, median (25th, 75th) 67.0 (58,75) 67.0 (58, 75) 67.0 (59, 73) 0.009
Females, n (%) 8363 (36.9) 7369 (37.5) 994 (32.8) <0.001
Body surface area (m2), median
(25th, 75th)
1.961 (1.801, 2.112) 1.967 (1.806, 2.123) 1.918 (1.779, 2.048) <0.001
Body mass index, median (25th, 75th) 26.95 (24.30, 30.51) 27.12 (24.39, 30.73) 25.99 (23.80, 28.95) <0.001
Height, (m), median (25th, 75th) 1.702 (1.626, 1.778) 1.727 (1.626, 1.778) 1.702 (1.626, 1.778) <0.001
Weight (kg), median (25th, 75th) 79.8 (69, 91) 79.8 (69, 91) 76.2 (68, 85) <0.001
Previous MI, n (%) 6947 (30.7) 5736 (29.2) 1211 (40.0) <0.001
Diabetes history, n (%) 5729 (25.3) 5135 (26.2) 594 (19.6) <0.001
Previous CABG, n (%) 3235 (14.3) 2900 (14.8) 335 (11.1) <0.001
Peripheral vascular disease, n (%) 2606 (11.5) 2279 (11.6) 327 (10.8) 0.430
Left main coronary artery stenosis,
n (%)
3754 (16.6) 3400 (17.3) 354 (11.7) <0.001
Ejection fraction, n (%) <0.001
<35 5346 (23.6) 4751 (24.2) 595 (19.7)
35–49 3573 (15.8) 3204 (16.3) 369 (12.2)
>49 3481 (15.4) 2978 (15.2) 503 (16.6)
Missing 10263 (45.3) 8703 (44.3) 1560 (51.5)
MI=myocardial infarction; CABG=coronary artery bypass graft.
aP values for patient age, weight, body surface area, and body mass index were obtained from a one-way comparison of the ranks within the
combined sample. P values for all other characteristics were obtained using a chi-square test.
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comparisons to the full model and model-fitting diagnostics
were used to judge whether predictive value was lost by remov-
ing factors and or interactions. Finally, candidate factors
were fitted to a randomly selected subset of records and the
resulting logistic regression model coefficients were used
to discriminate the mortality/non-mortality subgroups from
another disjoint subset of records by computing the predicted
logits and measuring the resulting separation of the mortality/
non-mortality subgroups.
The risk factors and models differed depending on whether
or not patients had a surgical cardiac intervention. Factors that
were common to both surgical cardiac and non-surgical cardiac
predictor models were age >75 years, body surface area (BSA),
initial pre-IABP systolic blood pressure, ejection fraction <30%,
peripheral vascular disease, wait for IABPP5 days after hospital
admission, insertion year, indication for use listed as ‘cardio-
genic shock’, ‘unstable refractory angina’, or ‘support and
stabilization’. Additional factors in the model for patients
with surgical cardiac interventions included gender, primary
diagnosis=acute myocardial infarction (AMI), previous coronary
artery bypass graft (CABG), indication for use ‘wean from
cardiopulmonary bypass’, or ‘pre-operative high-risk CABG’.
Additional factors in the model for patients with non-surgical
cardiac interventions included history of diabetes, previous MI,
andP3 vessel disease. The observed US and non-US mortalities
were then computed within predicted risk quartiles generated
from these logistic regression models, and this provided a
Table 2 IABP Indications, insertion characteristics, and duration indices
Total
n=22 663
US institutions
n=19 636
Non-US institutions
n=3027
P
value
Indication for use, n (%)a <0.001
Support and stabilization for angiography and
angioplasty
4500 (19.9) 4143 (21.1) 357 (11.8)
Cardiogenic shock 4314 (19.0) 3702 (18.9) 612 (20.2)
Wean from cardiopulmonary bypass 3664 (16.2) 2811 (14.3) 853 (28.2)
Pre-operative high-risk CABG 3319(14.6) 3118 (15.9) 201 (6.6)
Unstable refractory angina 2618 (11.6) 2296 (11.7) 322 (10.6)
Refractory ventricular failure 1515 (6.7) 1219 (6.2) 296 (9.8)
Mechanical complications of AMI 1235 (5.4) 1085 (5.5) 150 (5.0)
Not indicated; miscellaneous, other
(intraoperative pulsatile flow)
960 (4.2) 829 (4.2) 131 (4.3)
Ischaemia: intractable ventricular arrhythmia 378 (1.7) 290 (1.5) 88 (2.9)
Cardiac support for high-risk surgery 160 (0.7) 143 (0.7) 17 (0.6)
SBP before insertion (mmHg) median (25th, 75th) 107.0 (87.0, 129.0) 110.0 (90.0, 131.0) 90.0 (73.0, 110.0)
IABP insertion location, n (%)a <0.001
Catheterization laboratory 13 990 (61.7) 12 797 (65.2) 1193 (39.4)
Operating room 5571 (24.6) 4348 (22.1) 1223 (40.4)
Other, not indicateda 3102 (13.7) 2491 (12.7) 611 (20.2)
Length of hospital stay, days, median (25th, 75th) 11.0 (7, 17) 10.0 (7, 16) 15.0 (10, 23) <0.001
IABP insertion P5 days after admission, n (%) 3196 (14.1) 2677 (13.6) 519 (17.1) <0.001
Days from insertion to discharge, median
(25th, 75th)
9.0 (7, 15) 9.0 (6,14) 12.0 (9, 20) <0.001
Days balloon in place, median (25th, 75th) 3.0 (2, 4) 3.0 (2, 4) 3.0 (2, 4) 0.008
Last cardiac surgical intervention prior to IABP,
n (%)
13 810 (60.9) 11 729 (59.7) 2081 (68.7) <0.001
CABG, n (%) 12 663 (55.9) 10 510 (53.1) 1453 (48.0))
Non-CABG, n (%) 1547 (6.8) 1219 (6.2) 328 (10·8)
Last PCI prior to IABP, n (%) 8853 (39.1) 7907 (40.2) 946 (31.3) <0.001
Interventional cardiology, n (%) 5157 (22.7) 4712 (24.0) 445 (14.7)
Diagnostic catheterization, n (%) 2147 (9.5) 1908 (9.7) 239 (7.8)
Last intervention not recorded, n (%) 1549 (6.8) 1287 (6.6) 262 (8.7) <0.001
CABG=coronary artery bypass graft; AMI=acute myocardial infarction; SBP=systolic blood pressure; PCI=percutaneous cardiac intervention.
aOther=open heart recovery unit, intensive care unit, coronary care unit, and emergency room; percentages do not always total 100% due to missing
data.
Table 3 Prophylactica IABC use: incidence by insertion
yearb
US institutions Non-US institutions P value
1997 463/2684 (17.3%) c
1998 971/4720 (20.6%) 48/426 (11.3%) <0.0005
1999 1387/5344 (26.0%) 102/892 (11.4%) <0.0005
2000 1517/4850 (31.3%) 224/1138 (19.7%) <0.0005
2001 576/1842 (31.3%) 96/473 (20.3%) <0.0005
aProphylactic use is defined as balloon insertion before last
intervention.
bComparisons made using chi-square test on unadjusted rates.
cIn 1997 there were less than 100 international entries.
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graphical summary of the mortality experience within patient
subgroups having similar mortality risk. By subdividing the
patients into groups according to the quartiles determined by
their estimated risk of death and then comparing the observed
mortalities within these risk quartiles, we had the opportunity of
observing not just one US/non-US difference, but several differ-
ences depending on the patient risk. The formal adjusted
comparisons of mortalities were then accomplished by including
a US/non-US factor in both the surgery and non-surgery logistic
regression models to generate odds ratios from the factor coef-
ficients. For this study, the criterion for statistical significance
was P=0.05 and was not adjusted for multiple comparisons.
We analysed risk adjusted mortality rates after excluding all
countries that contributed less than 98 cases (Appendix A) and
found no change in the results. All analyses were performed
using SAS, version 8, using the Windows 98 operating system for
an IBM compatible PC.
Endpoints
The primary endpoints included major limb ischaemia, severe
bleeding, IABP failure (balloon failure and balloon leak), and all
cause in-hospital mortality. All cause in-hospital mortality was
defined as mortality occurring from any cause during IABP or
after IABP. A secondary endpoint was major IABP-related com-
plications, defined as any major limb ischaemia, severe bleed-
ing, IABP leak, or mortality directly attributed to IABP. Examples
of reasons for death attributable to IABP include stroke
and multiple emboli to gut with subsequent bowel infarction.
Definitions of all endpoints have been previously published.4
Results
A series of independent audits used to validate the
registry revealed that virtually all IABP procedures at
participating sites were included. In addition, accuracy
rates were P95% for most categorical variables and
P80% for quantitative variables that required a written
answer.5 The high rates of agreement between registry
data and patient records support the reliability of the
data.
Baseline clinical characteristics for the total popu-
lation, for US patients, and for non-US patients are shown
in Table 1. More US patients were women, had previous
CABG surgery, or diabetes, or had an ejection fraction
<35%. US patients also tended to be slightly older, taller,
heavier, and have a greater body surface area (BSA) and
body mass index (BMI). In contrast, more non-US patients
had a history of myocardial infarction (MI).
Indications and insertion characteristics
Due to the large number of patients, most of the differ-
ences between the US and non-US sites are statistically
significant. Thus, we emphasize only the major differ-
ences. Overall, the indications and locations of insertion
were significantly different (P<0.001). Specifically, a
greater percentage of IABP use, at US compared to
non-US centres, was to provide early support and stabil-
ization of patients undergoing angiography and angio-
plasty (21.1% US vs 11.8% non-US), or pre-operative
support for high-risk CABG (15.9% vs 6.6%). A smaller
percentage of IABP use, at US compared to non-US
centres, was for weaning from cardiopulmonary bypass
(14.3% vs 28.2%), or refractory ventricular failure (6.2% vs
9.8%) (Table 2). Roughly similar percentages of patients
in both groups had IABP for pre-operative support for
high-risk general surgery (0.7% vs 0.6%), or for cardio-
genic shock (18.9% vs 20.2%). The average length of stay
(P<0.001), the number of days from insertion to discharge
(P<0.001), and the number of days with IABP in place
(P=0.008) were lower in US compared to non-US insti-
tutions. Time from hospital admission to IABP insertion
was shorter for patients at US centres, with 13.6% of
patients receiving IABP P5 days from admission as com-
pared with 17.1% at non-US centres. In the US, 65.2% of
insertions were in the catheterization laboratory versus
39.4% in non-US facilities (Table 2). The majority of
insertions in non-US sites occurred in the operating room.
The insertion was sheathless in 16.6% of US cases and in
41.5% of non-US cases. Lastly, prophylactic IABP use,
defined as balloon insertion before last intervention, has
increased over time, and is higher in US institutions
(31.3% US vs 20.3% non-US in 2001, Table 3).
Complications and mortality rates
Complication and mortality rates, regardless of location,
were low, and in specific, major complication rates
(IABP-related mortality, balloon failure, balloon leak,
major limb ischaemia, and severe bleeding) were
extremely low (Table 4). In contrast, overall mortality
Table 4 Major complication and unadjusted mortality rates for US and non-US institutionsa
Total n=22 663 US institutions n=19 636 Non-US institutions n=3027 P value
All cause in-hospital mortality, n (%) 4819 (21.3) 3951 (20.1) 868 (28.7) <0.001
Mortality: balloon in place, n (%) 2669 (11.8) 2125 (10.8) 544 (18.0) <0.001
Overall major IABP related complications
IABP-related mortality n (%) 12 (0.053) 10 (0.051) 2 (0.066) 0.736
Major limb ischaemia, n (%) 194 (0.9) 169 (0.9) 25 (0.8) 0.847
Severe bleeding, n (%)b 196 (0.9) 173 (0.9) 23 (0.8) 0.790
Balloon failure/leak, n (%) 827 (3.6) 704 (3.6) 123 (4.1) 0.341
IABP=intra-aortic balloon pump.
aThe chi-square test was used on unadjusted rates.
bBleeding at IABP insertion site.
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rates in this seriously ill population remain high at
more than 20%. In the Benchmark registry, all cause
unadjusted in-hospital mortality, and mortality with IABP
in place, were significantly lower at US institutions
(20.1% US vs 28.7% non-US, P<0.001), and (10.8% vs
18.0%, P<0.001) (Table 4). An investigation of all cause
in-hospital mortality and mortality with balloon in place
by insertion year reveals that both are consistently higher
in non-US institutions (Table 5).
Since it is possible for mortality rates to be higher in
non-US sites because patients were simply at higher risk
and had more comorbidity, we adjusted for risk factors
and analysed the data with multiple logistic regression
analysis. After adjusting for risk factors, patients in
non-US institutions were still at higher risk for mortality.
Patient data were subsequently divided into groups
according to predicted mortality based on risk factors.
For patients with non-surgical cardiac interventions,
mortality in non-US sites was consistently higher in every
risk group (Fig. 1). Similarly, mortality was higher in
non-US sites for patients with surgical cardiac inter-
ventions, although the differences were not consistently
significant (Fig. 2). Mortality was significantly higher
for non-US patients with non-surgical cardiac inter-
ventions whose primary indication was cardiogenic
shock (adjusted odds ratio, [95%CI]=1.54, [1.27, 1.87];
P<0.001) (Fig. 3).
The logistic regression model that included a non-US
versus US term revealed that non-US patients with surgi-
cal cardiac interventions had higher all cause in-hospital
mortality (adjusted odds ratio, [95% confidence interval
(CI)]=1.34, [1.21, 1.49]; P<0.001). Non-US patients with
non-surgical cardiac interventions also had high all cause
in-hospital mortality (adjusted odds ratio, [95% CI]=1.72,
[1.51, 1.95]; P<0.001).
Mortality with balloon in place was also higher in
non-US patients with both surgical cardiac interventions
(adjusted odds ratio, [95% CI]=1.48, [1.31, 1.68];
P<.0.001) and with non-surgical cardiac interventions
(adjusted odds ratio, [95% CI]=1.74, [1.50, 2.02];
P<0.001).
Discussion
In US and non-US institutions, IABP is generally associated
with a low rate of major complications. However, all
cause in-hospital mortality and mortality with balloon in
place are higher in non-US sites even after adjusting for
risk factors. Potential reasons for this difference in mor-
tality rates include the greater use of IABP in a prophy-
lactic mode at US centres and at an earlier time point in
the patients’ illness. Whereas the prophylactic use of
IABP has also increased at non-US centres, corresponding
reductions in mortality may have not been realized as the
rate of IABP use for more indications in high-risk patients
has also increased. IABP insertion location was more
commonly in the catheterization laboratory in US centres
and more commonly in the operating room in non-US
centres. This difference in insertion location may reflect
differences in indications for IABP use — non-US centres
use IABPs for surgical cardiac interventions more fre-
quently than US centres. Previous studies support the
notion that having a catheterization laboratory can
affect treatment approaches and outcomes. For
example, the GRACE investigators found substantial
differences in treatment approach according to teaching
status, presence of catheterization laboratory, and geo-
graphic region.6,7 However, the presence or absence of a
catheterization laboratory in the GRACE study was not
shown to affect mortality.7
Hospital length of stay is also longer in non-US
sites. This may be a result of the selection of high-risk
patients for IABP. Patients at non-US institutions may also
receive their IABP later in the course of their treatment.
Combined with lower rates of prophylactic IABP use at
non-US sites, this may explain some of the observed
differences in mortality rates. It is also possible that US
centres may use IABP more commonly in patients who are
destined to do well.
Many large international trials have demonstrated
substantial variability in outcomes among different
countries.8–10 For example, after adjusting for baseline
characteristics, enrolment in the United States was found
Table 5 In-hospital mortality and mortality with balloon in place — incidence by insertion yeara,b
Total US institutions Non-US institutions P value
In-hospital mortality
1997 558/2776 (20.1%) 536/2684 (20.0%) 22/92 (23.9%) 0.353
1998 1039/5146 (20.2%) 916/4720 (19.4%) 123/426 (28.9%) <0.001
1999 1393/6236 (22.3%) 1129/5344 (21.1%) 264/892 (29.6%) <0.001
2000 1249/5988 (20.9%) 965/4850 (19.9%) 284/1138 (25.0%) <0.001
2001 545/2315 (23.5%) 371/1842 (20.1%) 174/473 (36.8%) <0.001
Mortality: ballon in place
1997 316/2776 (11.4%) 305/2684 (11.4%) 11/92 (12.0%) 0.860
1998 584/5146 (11.3%) 512/4720 (10.8%) 72/426 (16.9%) <0.001
1999 724/6236 (11.6%) 568/5344 (10.6%) 156/892 (17.5%) <0.001
2000 687/5988 (11.5%) 505/4850 (10.4%) 182/1138 (16.0%) <0.001
2001 339/2315 (14.6%) 216/1842 (11.7%) 123/473 (26.0%) <0.001
aData from 1996 are not included because there were so few international entries in that year.
bChi-square tests applied to unadjusted rates.
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to be a marginally significant predictor of better survival
in the GUSTO I trial.8 They also found that more compli-
cations were reported in the United States. Even in the
United States, there is great variation in the risk-
adjusted rates of IABP use between hospitals.11
Although IABP use has been shown to be cost-effective
and beneficial in high-risk patients,12–15 controversy per-
sists about appropriate indications for use because of the
historically high complication rates.16,17 However, major
complication rates in the Benchmark registry were small,
ranging from 0.9% to 2.7%. Physicians should therefore
have little reluctance to use IABP in high-risk patients
undergoing cardiac procedures. For example, IABP treat-
ment improves the outcomes of patients who have left-
main coronary disease,18 an ejection fraction of <0.25,19
who are undergoing repeat CABG surgery,20 or are under-
going cardiac catheterization during myocardial infarc-
tion.14 However, Stone et al, demonstrated no difference
in mortality with prophylactic treatment with IABP versus
conservative treatment in patients with acute myocar-
dial infarction undergoing percutaneous transluminal
coronary angioplasty,21 although the event rate was
extremely low (4.3% vs 3.1%; n=437).
Limitations
The limitations of this study are inherent to any large-
scale post hoc analysis of prospectively gathered data.
Because the registry contains a high number of patients,
a difference of just 1% will likely have a significant
P-value. Although the differences are unlikely to be
attributed solely to chance, the clinical importance of
the differences must be judged with practical wisdom
and clinical experience. In addition, this is not a random-
ized trial; rather, it is a detailed description of ongoing
and evolutionary clinical practice. There may also be
site-to-site variations in personnel and resources allo-
cated to the registry, individual practice patterns, and
patient populations that are intrinsic to any multi-
national commercially-sponsored registry.
In the multiple logistic regression analysis, all possible
risk factors for mortality were not included in the model.
Variables that were not collected as part of the registry
could not be included in the analysis.
Conclusions
Indications for IABP use differ between non-US insti-
tutions and US institutions. US institutions use IAPB for
the early support and stabilization of patients undergoing
angiography and angioplasty, pre-operative support for
high-risk CABG, and cardiac support for high-risk surgery
more frequently than their non-US counterparts. Non-US
sites are more likely to use IABP in the treatment of
high-risk patients including treatment of cardiogenic
shock, weaning from cardiopulmonary bypass, and
refractory ventricular failure. Overall, major compli-
cation rates are low and physicians should be less reluc-
tant to use IABP in high-risk patients undergoing cardiac
procedures. Prophylactic use of IABP has increased over
Fig. 1 In-hospital mortality by predicted risk for patients with non-surgical cardiac interventions. Error bars indicate 95% confidence intervals. The
predicted mortality categories were based on a logistic regression model combining US and non-US sites. Category boundaries are quartiles of the
predicted in-hospital mortalities from the combined cohort of non-surgical cardiac interventions.
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time, and remains higher in US institutions. All cause
in-hospital mortality and mortality with balloon in
place are significantly higher for patients undergoing
non-surgical interventions at non-US sites even after
adjusting for risk factors.
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Fig. 2 In-hospital mortality by predicted risk for patients with surgical cardiac interventions. Error bars indicate 95% confidence intervals. The predicted
mortality categories were based on a logistic regression model combining US and non-US sites. Category boundaries are quartiles of the predicted
in-hospital mortalities from the combined cohort of surgical cardiac interventions.
Fig. 3 In-hospital mortality by predicted risk by primary indications. CG=cardiogenic. Category boundaries are quartiles of the predicted in-hospital
mortalities from the combined indications.
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Appendix A
Percentages do not total 100 due to
rounding; three missing values for non-US
sites
Country Number of patients
US sites n=19636
Non-US sites n=3024
n (%)
Canada 755 (25.0)
United Kingdom 710 (23.5)
Germany 521 (17.2)
Belgium 237 (7.8)
New Zealand 155 (5.1)
Ireland 149 (4.9)
Australia 98 (3.2)
France 86 (2.8)
South Africa 84 (2.8)
Denmark 51 (1.7)
Poland 47 (1.6)
Greece 39 (1.3)
Netherlands 34 (1.1)
Switzerland 25 (0.8)
Colombia 16 (0.5)
Scotland 13 (0.4)
Argentina 2 (0.1)
Mexico 2 (0.1)
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